Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/22646
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAlexander, Marliese-
dc.contributor.authorPavlakis, Nick-
dc.contributor.authorJohn, Thomas-
dc.contributor.authorO'Connell, Rachel-
dc.contributor.authorKao, Steven-
dc.contributor.authorHughes, Brett G M-
dc.contributor.authorLee, Adrian-
dc.contributor.authorHayes, Sarah A-
dc.contributor.authorHowell, Viive M-
dc.contributor.authorClarke, Stephen J-
dc.contributor.authorMillward, Michael-
dc.contributor.authorBurbury, Kate-
dc.contributor.authorSolomon, Benjamin-
dc.contributor.authorItchins, Malinda-
dc.date2020-01-22-
dc.date.accessioned2020-02-24T04:02:17Z-
dc.date.available2020-02-24T04:02:17Z-
dc.date.issued2020-01-22-
dc.identifier.citationLung Cancer 2020; 142: 34-40-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/22646-
dc.description.abstractThis study aimed to describe the longitudinal thromboembolism (TE) risk relative to the natural history of disease and clinical course of ROS1 rearranged non-small cell lung cancer (NSCLC). Cases of ROS1-rearranged NSCLC from six Australian hospitals were pooled and evaluated for incidence, timing, predictors and outcomes of venous or arterial TE, as well as objective response rate (ORR) to active therapy and overall survival (OS). Of 42 patients recruited, 20 (48%) experienced TE; one (2%) arterial, 13 (31%) a pulmonary emboli (PE), and 12 (29%) a deep vein thrombosis. Among those with TE, six (30%) experienced multiple events, three as concurrent and three as recurrent diagnoses. The cumulative incidence of TE over time, adjusted for death as a competing risk factor, approached 50%. TE occurred prior to, during and post the peri-diagnostic period and occurred irrespective of treatment strategy. A thrombophilia was identified in n = 3/10 (30%) cases screened: in two factor V Leiden and in one anti-thrombin III (ATIII) deficiency. Median OS was 21.3 months in those with TE vs. 28.8 months in those without; hazard ratio 1.16 (95%CI 0.43-3.15). Respective ORR to first-line therapy with TE was 50% vs. 44% without TE in the chemotherapy arm and 67% vs. 50% in the targeted therapy arm. In the rare cancer subtype, ROS1, these real-world data demonstrate sustained TE risk beyond the diagnostic period irrespective of therapeutic strategy. High incidence of PE, concurrent TE, and recurrent TE warrant validation in larger cohorts. Consideration of primary thromboprophylaxis in ROS1 populations is recommended.-
dc.language.isoeng-
dc.subjectNon-small cell lung cancer-
dc.subjectROS1-
dc.subjectThromboembolism-
dc.subjectvenous thromboembolism-
dc.titleA multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer.-
dc.typeJournal Article-
dc.identifier.journaltitleLung Cancer-
dc.identifier.affiliationDepartment of Pharmacy, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australiaen
dc.identifier.affiliationDepartment of Medical Oncology, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationDepartment of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australiaen
dc.identifier.affiliationOlivia Newton-John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationDepartment of Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australiaen
dc.identifier.affiliationDepartment of Medical Oncology, The Prince Charles Hospital, Chermside West, Queensland, Australiaen
dc.identifier.affiliationSchool of Medicine, University of Queensland, Brisbane, Queensland, Australiaen
dc.identifier.affiliationSydney Medical School, University of Sydney, Camperdown, New South Wales, Australiaen
dc.identifier.affiliationDepartment of Medical Oncology, Chris O'Brien Lifehouse, Camperdown, New South Wales, Australiaen
dc.identifier.affiliationOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationDepartment of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Victoria, Australiaen
dc.identifier.affiliationNHMRC Clinical Trial Centre, University of Sydney, Camperdown, New South Wales, Australiaen
dc.identifier.affiliationBill Walsh Translational Research Laboratory, Kolling Institute Medical Institute of Research, Royal North Shore Hospital, St Leonards, New South Wales, Australiaen
dc.identifier.affiliationNorthern Clinical School, University of Sydney, St Leonards, New South Wales, Australiaen
dc.identifier.affiliationNorthern Cancer Institute, St Leonards, New South Wales, Australiaen
dc.identifier.affiliationDepartment of Medical Oncology, Royal North Shore Hospital, St Leonards, New South Wales, Australiaen
dc.identifier.affiliationSir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australiaen
dc.identifier.affiliationDepartment of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australiaen
dc.identifier.affiliationSchool of Medicine, University of Western Australia, Perth, Western Australia, Australiaen
dc.identifier.doi10.1016/j.lungcan.2020.01.017-
dc.identifier.pubmedid32087434-
dc.type.austinJournal Article-
local.name.researcherJohn, Thomas
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

12
checked on Mar 27, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.